| Domain | Curated fact | Quantitative evidence | Suggested ontology IDs | Strongest source/date |
|---|---|---|---|---|
| Disease identity | Hereditary multiple osteochondromas (HMO), also called multiple osteochondromas, hereditary multiple exostoses, diaphyseal aclasis, and multiple cartilaginous exostoses, is a Mendelian skeletal disorder producing multiple cartilage-capped, corticomedullary-continuous bone outgrowths. | Diagnostic definition commonly requires ≥2 osteochondromas. | MONDO:0005508; Orphanet:321; OMIM:133700 and 133701 | Open Targets (pqac-00000000); D’Arienzo et al., 20-Dec-2019, DOI:10.2147/ORR.S183979 (pqac-00000001) |
| Causal genes | Heterozygous loss-of-function variants in **EXT1** or **EXT2** are the principal causes; their Golgi-resident glycosyltransferase complex polymerizes heparan sulfate. | EXT1/EXT2 variants explain approximately 70–95% of cases; earlier studies reported EXT1 in 28–65% and EXT2 in 21–61%. | HGNC:3512 (**EXT1**); HGNC:3513 (**EXT2**); GO:0000139, Golgi membrane; GO:0015012, heparan sulfate proteoglycan biosynthetic process | Open Targets (pqac-00000000); PMID:10639137; PMID:11391482 (pqac-00000003, pqac-00000023) |
| Inheritance and prevalence | HMO is autosomal dominant with variable expressivity and nearly complete, partly sex-dependent penetrance. | Prevalence approximately 1:50,000 in Western populations; reported penetrance approximately 100% in males and 96% in females; recurrence risk for an affected heterozygous parent is 50% per pregnancy. | HP:0000006, autosomal dominant inheritance; HP:0003829, incomplete penetrance | D’Arienzo et al., 2019, DOI:10.2147/ORR.S183979 (pqac-00000001) |
| Onset and course | Lesions are rarely apparent at birth, emerge in early childhood, enlarge while physes are open, and generally stop growing at skeletal maturity. | Median diagnosis approximately 3 years; visible lesion in 50% by age 5 and 80% by age 10; >80% present during the first decade. | HP:0011463, childhood onset; HP:0003674, onset in infancy | Tepelenis et al., Jan-2021, DOI:10.21873/invivo.12308 (pqac-00000016, pqac-00000017) |
| Core phenotype | Multiple sessile or pedunculated cartilage-capped osteochondromas arise mainly near growth plates and on surfaces of flat bones. | Mean reported burden approximately six lesions; common sites include distal femur 30%, proximal tibia 15–20%, and humerus 10–20%. | HP:0000934, multiple exostoses; HP:0030434, osteochondroma | Tepelenis et al., 2021, DOI:10.21873/invivo.12308 (pqac-00000016, pqac-00000017) |
| Musculoskeletal morbidity | Common consequences include short or disproportionate stature, limb bowing, forearm deformity, genu or ankle valgum, limb-length inequality, restricted joint motion, bursitis, and premature osteoarthritis. | In 158 children, 80.4% developed new lesions, 57.6% new deformities, and 23.4% new functional limitations; 46.2% showed progression. | HP:0004322, short stature; HP:0002970, genu valgum; HP:0001376, limitation of joint mobility; HP:0002814, abnormality of the lower limb | Mordenti et al., Oct-2020, DOI:10.1016/j.bone.2020.115499 (pqac-00000015) |
| Pain, fatigue, and quality of life | Chronic mechanical pain and fatigue substantially impair physical, psychosocial, occupational, and social functioning in adults. | Among 353 adults, pain affected 87.8% (NRS 3.19±2.6) and fatigue 90.4% (NRS 4.1±2.6); CIS fatigue was 84.1±15.3 and exceeded healthy and rheumatoid-arthritis references (p<0.001). | HP:0012531, pain; HP:0012378, fatigue | Amajjar et al., 17-Jul-2024, DOI:10.1371/journal.pone.0305640 (pqac-00000013) |
| Pathogenesis | Germline EXT haploinsufficiency lowers systemic heparan sulfate; a local somatic second hit can create EXT-null growth-plate or perichondrial cells, disrupting morphogen distribution and promoting ectopic chondrogenesis. | Human blood shows an approximately 50% reduction in the heparan-sulfate:chondroitin-sulfate ratio; loss of heterozygosity was found in 6 of 8 analyzed osteochondromas in one series. | GO:0030201, heparan sulfate proteoglycan metabolic process; GO:0061035, regulation of cartilage development; CL:0000138, chondrocyte | PMID:23514715; PMIDs:10441575, 17341731, 20813973 (pqac-00000023, pqac-00000025, pqac-00000027) |
| Signaling consequences | Heparan-sulfate deficiency alters BMP, Indian hedgehog/PTHrP, FGF–MEK–ERK, and WNT/β-catenin signaling; increased pro-chondrogenic BMP/hedgehog activity and reduced anti-chondrogenic FGF signaling are chiefly supported by model systems. | No validated clinical pathway biomarker or disease-specific omics diagnostic is available. | GO:0030509, BMP signaling pathway; GO:0007224, smoothened signaling pathway; GO:0008543, fibroblast growth factor receptor signaling pathway; GO:0016055, Wnt signaling pathway | Pacifici, Jun-2018, DOI:10.1080/21678707.2018.1483232; PMID:23458899 (pqac-00000002, pqac-00000027) |
| Diagnosis | Diagnosis is clinical-radiographic: multiple lesions with continuity of lesion cortex and medulla with the parent bone. Radiography is first line; CT defines complex anatomy, and MRI evaluates cartilage caps, neurovascular or spinal complications, and malignancy. | Suspicious findings include new pain or growth after maturity and cartilage-cap thickness >2 cm in adults or >3 cm in children. | HP:0000934; NCIT:C38101, radiography; NCIT:C16809, magnetic resonance imaging; NCIT:C17204, computed tomography | Tepelenis et al., 2021, DOI:10.21873/invivo.12308 (pqac-00000016, pqac-00000021) |
| Genetic testing | Recommended testing begins with sequencing of **EXT1** and **EXT2**, followed by deletion/duplication analysis; unresolved cases may require genome or RNA analysis for mosaic, deep-intronic, or structural variants. **PTPN11** analysis is relevant when metachondromatosis or an overlapping phenotype is suspected. | Conventional EXT testing yields approximately 78–95%; 10–20% can remain unresolved after coding-region and copy-number analysis. | NCIT:C101293, genetic testing; NCIT:C18477, molecular diagnostic testing | Borovikov et al., Feb-2024, DOI:10.1155/2024/8849348 (pqac-00000009) |
| Malignant transformation | The principal life-threatening complication is secondary peripheral chondrosarcoma arising from an osteochondroma cartilage cap; estimates vary by ascertainment, so specialist-center percentages should not be generalized. | Population-oriented estimates are approximately 0.5–5% or up to 3.9%. In 105 affected cases, median diagnosis was 34 years; pelvis accounted for 44%, and grade 2/3 disease or partial resection predicted worse disease-free survival. | NCIT:C121924, secondary peripheral chondrosarcoma; HP:0002664, neoplasm | Gnoli et al., Feb-2024, DOI:10.1186/s13023-023-03006-8 (pqac-00000012) |
| Management | No approved disease-modifying therapy exists for HMO. Asymptomatic lesions are observed; surgery is used for pain, deformity, functional or neurovascular compromise, fracture, or suspected malignancy. Procedures include complete excision, corrective osteotomy, hemiepiphysiodesis, and limb lengthening. | Complete excision has reported recurrence below 2%; postoperative complications approximately 11.6–12.5%. Evidence that forearm reconstruction improves long-term function or quality of life remains weak. | NCIT:C15329, surgical procedure; NCIT:C52003, excision; NCIT:C51932, osteotomy; NCIT:C15214, rehabilitation | Tepelenis et al., 2021, DOI:10.21873/invivo.12308 (pqac-00000021); Beltrami et al., May-2016, DOI:10.11138/ccmbm/2016.13.2.110 (pqac-00000004) |
| Recent genetics | A 2024 cohort expanded the recognized genetic overlap with metachondromatosis and showed that restricting testing to EXT1/EXT2 may miss relevant diagnoses. | Among 244 unrelated probands, 177 unique variants were detected across three genes—80 known and 97 novel; five osteochondroma-only cases carried **PTPN11** loss-of-function variants. | HGNC:9644 (**PTPN11**); MONDO:0008162, metachondromatosis | Borovikov et al., Feb-2024, DOI:10.1155/2024/8849348 (pqac-00000009) |
| Experimental therapy | The RARγ agonist palovarotene suppresses osteochondroma growth in mice but is not approved for HMO; pediatric safety concern centers on premature physeal closure. | In mice, treated tumors remained 0.31±0.049 mm³ versus 0.27±0.031 mm³ initially (p=0.66), while controls reached 1.03±0.23 mm³; phase 2 HMO trial NCT03442985 was terminated. | CHEBI:177944, palovarotene; NCIT:C96038, retinoic acid receptor gamma agonist | Garcia et al., 11-Jul-2024, DOI:10.3390/ijms25147610 (pqac-00000014); ClinicalTrials.gov NCT03442985 (pqac-00000011) |
| Models | Conditional or clonal chondrocyte **Ext1** loss, compound **Ext1/Ext2** deficiency, and **ext2**-null zebrafish reproduce aspects of abnormal endochondral ossification and osteochondroma biology. Models strongly support the second-hit/low-heparan-sulfate mechanism but do not capture the full variable human phenotype. | Single heterozygous mice are largely normal; conditional biallelic or compound deficiency produces multiple lesions. | NCBI Taxon:10090, *Mus musculus*; NCBI Taxon:7955, *Danio rerio*; CL:0000138, chondrocyte | PMIDs:20080592, 20534475, 21310272, 16236767 (pqac-00000023, pqac-00000027, pqac-00000028) |
| Research infrastructure | Longitudinal registries integrate clinical, imaging, genetic, surgical, biospecimen, and quality-of-life data to define natural history and genotype–phenotype associations. | Italian REM registry NCT04133285 plans enrollment of 10,000 and follow-up through 2032. | NCIT:C61393, patient registry; NCIT:C15273, longitudinal study | ClinicalTrials.gov NCT04133285, updated Nov-2025 (pqac-00000010) |


*Table: Compact evidence table summarizing the identity, genetics, natural history, clinical burden, diagnosis, management, recent findings, and experimental models of hereditary multiple osteochondromas. Quantitative findings and ontology suggestions are paired with the strongest available cited sources.*